Alex J. Eustace

1.8k total citations · 1 hit paper
52 papers, 1.2k citations indexed

About

Alex J. Eustace is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Alex J. Eustace has authored 52 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 28 papers in Molecular Biology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Alex J. Eustace's work include HER2/EGFR in Cancer Research (23 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Melanoma and MAPK Pathways (6 papers). Alex J. Eustace is often cited by papers focused on HER2/EGFR in Cancer Research (23 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Melanoma and MAPK Pathways (6 papers). Alex J. Eustace collaborates with scholars based in Ireland, United States and United Kingdom. Alex J. Eustace's co-authors include John Crown, Martin Clynes, Norma O’Donovan, Martina S.J. McDermott, Denis M. Collins, Laura Breen, Britta Stordal, Bryan T. Hennessy, Sinéad Toomey and Catharine West and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Alex J. Eustace

49 papers receiving 1.2k citations

Hit Papers

CARBON DOTS: Bioimaging and Anticancer Drug Delivery 2024 2026 2025 2024 20 40 60
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. CARBON DOTS: Bioimaging and Anticancer Drug Delivery
    2024 66 citations Michał Bartkowski, Alex J. Eustace et al. Chemistry - A European Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alex J. Eustace Ireland 20 688 429 347 163 93 52 1.2k
Zhixing Guo China 14 459 0.7× 350 0.8× 162 0.5× 166 1.0× 90 1.0× 37 1.1k
Sven A. Lang Germany 24 928 1.3× 449 1.0× 298 0.9× 174 1.1× 51 0.5× 44 1.5k
Yi-Wen Chu Taiwan 8 806 1.2× 305 0.7× 389 1.1× 128 0.8× 122 1.3× 8 1.3k
Flonné Wildes United States 21 849 1.2× 426 1.0× 517 1.5× 140 0.9× 128 1.4× 43 1.4k
Britta Stordal Ireland 15 665 1.0× 637 1.5× 228 0.7× 129 0.8× 30 0.3× 30 1.3k
Bea Pauwels Belgium 16 439 0.6× 356 0.8× 188 0.5× 209 1.3× 87 0.9× 30 949
Yeuan Ting Lee Malaysia 6 498 0.7× 300 0.7× 192 0.6× 139 0.9× 42 0.5× 9 1.0k
Byung-In Moon South Korea 20 479 0.7× 341 0.8× 308 0.9× 118 0.7× 95 1.0× 70 1.1k
Song Dong China 20 800 1.2× 355 0.8× 287 0.8× 510 3.1× 88 0.9× 79 1.4k
Yuxi Zhu China 17 492 0.7× 304 0.7× 479 1.4× 197 1.2× 54 0.6× 45 965

Countries citing papers authored by Alex J. Eustace

Since Specialization
Citations

This map shows the geographic impact of Alex J. Eustace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex J. Eustace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex J. Eustace more than expected).

Fields of papers citing papers by Alex J. Eustace

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex J. Eustace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex J. Eustace. The network helps show where Alex J. Eustace may publish in the future.

Co-authorship network of co-authors of Alex J. Eustace

This figure shows the co-authorship network connecting the top 25 collaborators of Alex J. Eustace. A scholar is included among the top collaborators of Alex J. Eustace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex J. Eustace. Alex J. Eustace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Miceli, Rosalba, Hanna Eriksson, Giuseppe Lo Russo, et al.. (2024). Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study. Acta Oncologica. 63. 213–219. 3 indexed citations
2.
3.
Bartkowski, Michał, et al.. (2024). CARBON DOTS: Bioimaging and Anticancer Drug Delivery. Chemistry - A European Journal. 30(19). e202303982–e202303982. 66 indexed citations breakdown →
4.
Roche, Sandra, Patricia Gaule, Nupur Mukherjee, et al.. (2023). Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer. PLoS ONE. 18(3). e0282512–e0282512. 6 indexed citations
5.
Miceli, Rosalba, Hanna Eriksson, Alex J. Eustace, et al.. (2021). 1795P Gender difference in side effects of immunotherapy: A possible clue to optimize cancer treatment. Annals of Oncology. 32. S1223–S1224. 4 indexed citations
6.
Breen, Laura, Patricia Gaule, Alexandra Canonici, et al.. (2020). Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A. Investigational New Drugs. 38(5). 1365–1372. 10 indexed citations
7.
Kennedy, Sean P., Michael F. O‘Neill, Patrick G. Morris, et al.. (2020). Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer. Oncogene. 39(14). 3028–3040. 31 indexed citations
8.
Gaule, Patricia, Nupur Mukherjee, B. Corkery, et al.. (2019). Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells. Cancers. 11(4). 548–548. 19 indexed citations
9.
Canonici, Alexandra, Neil T. Conlon, Denis M. Collins, et al.. (2018). The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells. Investigational New Drugs. 36(4). 581–589. 19 indexed citations
10.
Toomey, Sinéad, Stephen F. Madden, Simon J. Furney, et al.. (2016). The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer. Oncotarget. 7(46). 75518–75525. 10 indexed citations
11.
Eustace, Alex J., et al.. (2015). Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma. International Journal of Oncology. 47(3). 900–908. 17 indexed citations
12.
13.
Collins, Dearbhaile Catherine, Sinéad Cocchiglia, Paul Tibbitts, et al.. (2014). Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer. Oncogene. 34(4). 525–530. 23 indexed citations
14.
Hunter, Benjamin, Alex J. Eustace, Joely J. Irlam, et al.. (2014). Expression of hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancer. British Journal of Cancer. 111(3). 437–443. 34 indexed citations
15.
McDermott, Martina S.J., Alex J. Eustace, Laura Breen, et al.. (2014). In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies. Frontiers in Oncology. 4. 40–40. 234 indexed citations
16.
Hall, John, Janet Taylor, Helen Valentine, et al.. (2012). Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. British Journal of Cancer. 107(4). 684–694. 111 indexed citations
17.
Brougham, Dermot F., et al.. (2011). Artificial neural networks in metabolomic studies of human lung carcinoma cell lines by in vitro 1H nuclear magnetic resonance of whole cells. BioMed Research International. 4 indexed citations
18.
Roberts, Darren L., Kaye J. Williams, R. Cowen, et al.. (2009). Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. British Journal of Cancer. 101(8). 1290–1297. 42 indexed citations
19.
Glynn, Sharon A., DERMOT A. O'SULLIVAN, Alex J. Eustace, Martin Clynes, & Norma O’Donovan. (2008). The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer. 8(1). 9–9. 88 indexed citations
20.
Eustace, Alex J., John Crown, Martin Clynes, & Norma O’Donovan. (2008). Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. Journal of Translational Medicine. 6(1). 53–53. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhixing Guo Breakdown of academic impact, for papers by Sven A. Lang Breakdown of academic impact, for papers by Yi-Wen Chu Breakdown of academic impact, for papers by Flonné Wildes Breakdown of academic impact, for papers by Britta Stordal Breakdown of academic impact, for papers by Bea Pauwels Breakdown of academic impact, for papers by Yeuan Ting Lee Breakdown of academic impact, for papers by Byung-In Moon Breakdown of academic impact, for papers by Song Dong Breakdown of academic impact, for papers by Yuxi Zhu
Rankless by CCL
2026